NQO1-Bioactivatable Therapeutics as Radiosensitizers for Cancer Treatment
Developing cancer therapeutics that radiosensitize in a tumor-selective manner remains an ideal. We developed a novel means of radiosensitization, exploiting NAD(P)H:Quinone Oxidoreductase 1 (NQO1) overexpression, and lowered catalase expression in solid human tumors using NQO1-bioactivatable drugs....
Guardado en:
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2020
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/70814 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares: NQO1-Bioactivatable Therapeutics as Radiosensitizers for Cancer Treatment
- Radiosensitization Strategies Through Modification of DNA Double-Strand Break Repair
- Radiosensitization with Hyperthermia and Chemotherapeutic Agents: Effects on Linear-Quadratic Parameters of Radiation Cell Survival Curves
- Histone Acetyltransferases (HATs) Involved in Non-Homologous End Joining as a Target for Radiosensitization
- DNA Radiosensitization: The Search for Repair Refractive Lesions Including Double Strand Breaks and Interstrand Crosslinks
- Validation of Growth Differentiation Factor (GDF-15) as a Radiation Response Gene and Radiosensitizing Target in Mammary Adenocarcinoma Model
- Therapeutic Hypothermia in Acute Stroke